118 related articles for article (PubMed ID: 38915397)
1. Towards a survival risk prediction model for metastatic NSCLC patients on durvalumab using whole-lung CT radiomics.
Patwardhan KA; RaviPrakash H; Nikolaou N; Gonzalez-García I; Salazar JD; Metcalfe P; Reischl J
Front Immunol; 2024; 15():1383644. PubMed ID: 38915397
[TBL] [Abstract][Full Text] [Related]
2. Radiomics study for predicting the expression of PD-L1 in non-small cell lung cancer based on CT images and clinicopathologic features.
Sun Z; Hu S; Ge Y; Wang J; Duan S; Song J; Hu C; Li Y
J Xray Sci Technol; 2020; 28(3):449-459. PubMed ID: 32176676
[TBL] [Abstract][Full Text] [Related]
3. Combination of computed tomography imaging-based radiomics and clinicopathological characteristics for predicting the clinical benefits of immune checkpoint inhibitors in lung cancer.
Yang B; Zhou L; Zhong J; Lv T; Li A; Ma L; Zhong J; Yin S; Huang L; Zhou C; Li X; Ge YQ; Tao X; Zhang L; Son Y; Lu G
Respir Res; 2021 Jun; 22(1):189. PubMed ID: 34183009
[TBL] [Abstract][Full Text] [Related]
4. Radiomics-based prediction model for outcomes of PD-1/PD-L1 immunotherapy in metastatic urothelial carcinoma.
Park KJ; Lee JL; Yoon SK; Heo C; Park BW; Kim JK
Eur Radiol; 2020 Oct; 30(10):5392-5403. PubMed ID: 32394281
[TBL] [Abstract][Full Text] [Related]
5. Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics.
Dercle L; Fronheiser M; Lu L; Du S; Hayes W; Leung DK; Roy A; Wilkerson J; Guo P; Fojo AT; Schwartz LH; Zhao B
Clin Cancer Res; 2020 May; 26(9):2151-2162. PubMed ID: 32198149
[TBL] [Abstract][Full Text] [Related]
6. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
8. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
9. A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC.
Del Re M; Cucchiara F; Rofi E; Fontanelli L; Petrini I; Gri N; Pasquini G; Rizzo M; Gabelloni M; Belluomini L; Crucitta S; Ciampi R; Frassoldati A; Neri E; Porta C; Danesi R
Cancer Immunol Immunother; 2021 Jun; 70(6):1667-1678. PubMed ID: 33315149
[TBL] [Abstract][Full Text] [Related]
10. CT radiomics-based model for predicting TMB and immunotherapy response in non-small cell lung cancer.
Wang J; Wang J; Huang X; Zhou Y; Qi J; Sun X; Nie J; Hu Z; Wang S; Hong B; Wang H
BMC Med Imaging; 2024 Feb; 24(1):45. PubMed ID: 38360550
[TBL] [Abstract][Full Text] [Related]
11. Impact of feature selection methods and subgroup factors on prognostic analysis with CT-based radiomics in non-small cell lung cancer patients.
Sugai Y; Kadoya N; Tanaka S; Tanabe S; Umeda M; Yamamoto T; Takeda K; Dobashi S; Ohashi H; Takeda K; Jingu K
Radiat Oncol; 2021 Apr; 16(1):80. PubMed ID: 33931085
[TBL] [Abstract][Full Text] [Related]
12. Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images.
Tian P; He B; Mu W; Liu K; Liu L; Zeng H; Liu Y; Jiang L; Zhou P; Huang Z; Dong D; Li W
Theranostics; 2021; 11(5):2098-2107. PubMed ID: 33500713
[No Abstract] [Full Text] [Related]
13. Quantitative CT texture analysis in predicting PD-L1 expression in locally advanced or metastatic NSCLC patients.
Bracci S; Dolciami M; Trobiani C; Izzo A; Pernazza A; D'Amati G; Manganaro L; Ricci P
Radiol Med; 2021 Nov; 126(11):1425-1433. PubMed ID: 34373989
[TBL] [Abstract][Full Text] [Related]
14. CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer.
Ye G; Wu G; Zhang C; Wang M; Liu H; Song E; Zhuang Y; Li K; Qi Y; Liao Y
Front Immunol; 2024; 15():1414954. PubMed ID: 38933281
[TBL] [Abstract][Full Text] [Related]
15. A prognostic analysis method for non-small cell lung cancer based on the computed tomography radiomics.
Wang X; Duan H; Li X; Ye X; Huang G; Nie S
Phys Med Biol; 2020 Feb; 65(4):045006. PubMed ID: 31962301
[TBL] [Abstract][Full Text] [Related]
16. Development and Validation of a Machine Learning-Based Model Using CT Radiomics for Predicting Immune Checkpoint Inhibitor-related Pneumonitis in Patients With NSCLC Receiving Anti-PD1 Immunotherapy: A Multicenter Retrospective CaseControl Study.
Zhang GY; Du XZ; Xu R; Chen T; Wu Y; Wu XJ; Liu S
Acad Radiol; 2024 May; 31(5):2128-2143. PubMed ID: 37977890
[TBL] [Abstract][Full Text] [Related]
17. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
[TBL] [Abstract][Full Text] [Related]
18. SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2.
Mark M; Froesch P; Eboulet EI; Addeo A; Pless M; Rothschild SI; Janthur WD; Burmeister H; Friedlaender A; Schneider M; Metaxas Y; Joerger M; Wannesson L; Schwitter M; Baudoux N; Weindler S; Biaggi-Rudolf C; Früh M;
Cancer Immunol Immunother; 2021 May; 70(5):1255-1262. PubMed ID: 33130956
[TBL] [Abstract][Full Text] [Related]
19. Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis.
Sun W; Jiang M; Dang J; Chang P; Yin FF
Radiat Oncol; 2018 Oct; 13(1):197. PubMed ID: 30290849
[TBL] [Abstract][Full Text] [Related]
20. A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma.
Peng J; Zou D; Zhang X; Ma H; Han L; Yao B
J Transl Med; 2024 Jan; 22(1):87. PubMed ID: 38254087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
